ID   U-2030
AC   CVCL_M581
DR   Wikidata; Q54973543
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=3583453;
RX   PubMed=10936422;
CC   Characteristics: Produces IgA lambda.
CC   Doubling time: ~36 hours (PubMed=3583453).
CC   Miscellaneous: Cell line has been lost (PubMed=10936422).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: Plasma cell; CL=CL_0000786.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M585 ! U-2031
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 14-08-25; Version: 15
CH   CVCL_M582 ! U-2030 TG
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund, Helena
RA   Nilsson, Kenneth
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters, John R.W. & Palsson, Bernhard Orn (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler, Hans Gunther
RA   Matsuo, Yoshinobu
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=3583453; DOI=10.1002/ijc.2910390615;
RA   Jernberg-Wiklund, Helena
RA   Bjorklund, Gunilla
RA   Nilsson, Kenneth
RT   "Establishment of a new human myeloma cell line (U-2030) and selection
RT   of a HAT-sensitive subline.";
RL   Int. J. Cancer 39:745-751(1987).
//